Dr. Baihua Zhang 张百华
Chief Physician
Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Shenzhen
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Minimally invasive surgery for lung nodules, early-stage lung cancer, and esophageal cancer using single-port thoracoscopy and robotics. Surgical management of tracheal tumors, stenosis, and fistulas. Comprehensive treatment of chest wall, thymic, and mediastinal tumors.
Dr. Zhang holds a PhD in Oncology from Tsinghua University and Peking Union Medical College. Currently Deputy Director of Thoracic Surgery at Cancer Hospital, Chinese Academy of Medical Sciences, Shenzhen Center, Dr. Zhang was formerly Deputy Director at Hunan Cancer Hospital. A visiting scholar at MD Anderson Cancer Center, Dr. Zhang has published over 10 SCI papers and led or participated in 12 national and provincial projects.
Professional roles
- Vice Chair, Youth Committee of Thoracic Oncology Professional Committee, World Chinese Physicians Association
- Vice Chair, Youth Committee of Tumor Laparoscopic Minimally Invasive Therapy Professional Committee, Hunan Anti-Cancer Association
- Member, Esophageal Cancer Professional Committee, Hunan Anti-Cancer Association
- Reviewer, Journal of Thoracic Disease
Name order: in Chinese the family name comes first (Zhang Baihua). Papers usually list the name as Baihua Zhang or Zhang B.
Selected publications
14 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Oncol, 2026 (senior author): Artificial intelligence in esophageal cancer: a narrative review from a thoracic surgical perspective. PubMed 42979228
- Oncol Lett, 2025 (senior author): Reduction in surgical scope after neoadjuvant chemotherapy and immunotherapy for non-small cell lung cancer. PubMed 40917729
- Front Cell Dev Biol, 2025 (senior author): Nomogram for predicting pathological complete response to neoadjuvant chemoimmunotherapy in patients with resectable non-small cell lung cancer. PubMed 41059341
- Front Oncol, 2023 (first author): Neoadjuvant chemoimmunotherapy cycle number selection for non-small cell lung cancer and clinical outcomes: a real-world analysis. PubMed 37731645
- Front Immunol, 2023 (first author): Perioperative outcomes of neoadjuvant chemotherapy plus camrelizumab compared with chemotherapy alone and chemoradiotherapy for locally advanced esophageal squamous cell cancer. PubMed 36825006
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion